Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RAIsonance is a private AI healthtech company developing software-based respiratory screening and monitoring products that analyze Forced Cough Vocalizations captured on a smartphone. Its core platform, FCV Signature Analysis Technology, underpins products including AudibleHealth AI/AudibleHealth Dx for respiratory disease screening and FCV Sentinel for early warning and respiratory wellness monitoring. The company states that its solutions are available for tuberculosis and COVID-19, with pneumonia and influenza products in final testing and additional programs on its roadmap. Beyond diagnostics, RAIsonance also markets wellness and biometric applications built on cough and voice-derived data. The business is headquartered in Greenwood Village, Colorado and appears focused on scalable, low-cost, noninvasive digital respiratory health tools.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RAIsonance.